New Drug Product: Imbruvica

Treatment of patients with mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

Depression in Cancer Patients

Patients with cancer and depression frequently do not receive effective treatment.

Diabetes Risk for Lymphoma Survivors

Para-aortic radiation correlates with increased diabetes mellitus risk for Hodgkin's lymphoma survivors.

Colonic Diverticular Disease, Cancer

Colonic diverticular disease does not appear to be linked to an increased risk of subsequent colorectal cancer.

Botulinum Toxin as Cancer Treatment?

The therapeutic effects of systemic chemotherapy were enhanced by vagotomy or botulinum toxin type A treatment in a study.

Active Surveillance for Testicular Cancer

Active surveillance for clinical stage I (CSI) testis cancer leads to excellent outcomes.

NSAIDs, Breast Cancer Recurrence

Daily use of NSAIDs may reduce the recurrence rate of hormone-responsive breast cancer in overweight or obese women.

Prostate Cancer Treatments

Review this new chart on FDA-approved prostate cancer treatments for quick information when you need it.


Is Herceptin Best for HER2 Breast Cancer Patients?

Is Herceptin Best for HER2+ Breast Cancer Patients?

Trastuzumab (Herceptin) is the best drug treatment for human epidermal growth factor receptor 2-positive breast cancer and should remain the standard of care for that type of tumor, according to new research.

Amino Acids May Be Early Marker of Pancreatic Cancer

An increase in certain amino acids may be an early sign of pancreatic cancer, occurring before the disease is diagnosed and symptoms appear, reports a new study.

Adcetris Extends Survival in Post-Transplant Hodgkin Lymphoma Study

Seattle Genetics and Takeda announced results from the Phase 3 AETHERA trial with Adcetris (brentuximab vedotin) in patients with post-transplant Hodgkin lymphoma.

Combination Breast Cancer Therapy Extends Overall Survival

Roche announced results from the Phase 3 CLEOPATRA study evaluating the addition of Perjeta (pertuzumab; Genentech) to Herceptin (trastuzumab; Genentech) and docetaxel chemotherapy in patients with previously untreated HER2-positive metastatic breast cancer.

Cobimetinib + Zelborif Increased PFS in Melanoma Trial

Roche announced positive data from the coBRIM Phase 3 study with cobimetinib plus Zelboraf (vemurafenib) in patients with previously untreated BRAF V600 mutation-positive, advanced melanoma.


Make prescribing decisions with our comparative charts and treatment algorithms.


Quickly and accurately perform clinical calculations.

Patient Information Fact Sheets

Download or print easy-to-read disease leaflets for your patients.

Featured courses from mycme

The Brigham Board Review in Hematology and OncologyExternal web site

The Brigham Board Review in Hematology and Oncology offers expert preparation for your ABIM subspecialty ...

CME 42.00 Credits

Comprehensive Review of Radiation OncologyExternal web site

Radiation oncologists and residents will appreciate the experience of the renowned faculty of the Comprehensive ...

CME 23.00 Credits

Understanding Current and Emerging Therapies for Head and Neck CancersExternal web site

This activity can help oncology nurses refresh their knowledge of the risks and treatments for ...

CE 0.50 Credits

Sign Up for Free e-newsletters